Invitation to Cover:
"The Legacy of the Philadelphia Chromosome: From Discovery to Therapy"
A Symposium in Honor of Peter C. Nowell, MD
||In recognition of his over-fifty-year career at the
University of Pennsylvania School of Medicine, Dr.
Nowell and his colleagues from Penn and other institutions will talk
about the history of the Philadelphia chromosome and what it portends
for the next generation of cancer therapies. The Philadelphia chromosome
was first described in 1960 by Dr. Nowell at Penn and the late David
Hungerford from the Fox Chase Cancer Center’s Institute for
Cancer Research. It proved to be the first gene-based cause for cancer.
Understanding abnormalities in the replication of the chromosome led
to the eventual development of the genetically targeted cancer drug
Gleevec five years ago.
||Wednesday, September 13, 2006
8:45 a.m. - 4:30 p.m.
||University of Pennsylvania Museum of Archeology
3260 South St., Philadelphia, PA
|8:00 am - 8:45 am
|8:45 am - 9:15 am
Arthur Rubenstein, MBBCh, Dean of the Univeristy of Pennsylvania
School of Medicine
Peter C. Nowell, MD, Department of Pathology and Laboratory
Mark Tykocinski, MD, Chair of the Department of Pathology and
|9:15 am - 10:00 am
||The Philadelphia Chromosome: A discovery
ahead of its time
Janet Rowley, MD, University of Chicago
|10:00 am - 10:45 am
||MicroRNA genes in leukemogenesis
Carlo Croce, MD, Ohio State University
|10:45 am - 11:00 am
|11:00 am - 11:45 am
||The road from the discovery of tyrosine
phosphorylation to the development of tyrosine kinase inhibitors
Tony Hunter, PhD, Salk Institute for Biological Studies
|11:45 am - 1:30 pm
|1:30 pm - 1:45 pm
John Glick, MD, Abramson Cancer Center, Penn
Craig Thompson, MD, Abramson Cancer Center, Penn
|1:45 pm - 2:30 pm
||The development of targeted therapy in
the erbB system
Mark Greene, MD, PhD, FRCP, Department of Pathology and Laboratory
|2:30 pm - 3:15 pm
||Stem cells and prostate cancer
Owen Witte, MD, University of California, Los Angeles
|3:15 pm - 3:30 pm
|3:30 pm - 4:15 pm
||Translation of the Philadelphia Chromosome
into therapy for CML
Brian Druker, MD, Oregon Health & Science University
|4:15 pm - 4:30 pm
||Program Conclusion and Evaluation
Mark Greene, MD, PhD, FRCP
The symposium is sponsored by the Penn Department of Pathology and Laboratory
Medicine and is also offered as CME-certified course. Please contact Karen
Kreeger at (215) 349-5658 or email@example.com
if you plan to attend.
PENN Medicine is a $2.9 billion enterprise dedicated
to the related missions of medical education, biomedical research, and
high-quality patient care. PENN Medicine consists of the University of
Pennsylvania School of Medicine (founded in 1765 as the nation's first
medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.